Compound ID | 1781
LYT100
Class: Lysin
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against Staphylococcus aureus. Engineered lysostaphin that kills via hydrolysis of pentaglycine cross-links in the bacterial cell wall peptidoglycan |
| Description: | Engineered endolysin |
| Institute where first reported: | Lyticon LLC, Stealth Biologics, Dartmouth College New Hampshire |
| Year first mentioned: | 2019 |
| Highest developmental phase: | Preclinical |
| Development status: | Active (as of 2022) |
| External links: | |
| Citation: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467700/ |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.